However, the EML4-ALK chimeric protein activates AKT and ERK pathways in EGFR mutation–positive NSCLC [42], while NPM-ALK fusion promotes ERK and STAT3 pathways in anaplastic large cell lymphoma [43]. This evidence concerns the gene EML4 and non-small cell lung carcinoma.